Microbiotica

Microbiotica announced £36M ($48M) in Series C financing on October 16, 2026. Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.

Round details

The financing includes backing from British Business Bank, Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners. The company did not publish a valuation with the announcement.

• Round: Series C
• Capital announced: £36M ($48M)
• Headquarters: Chesterford Research Park, near Cambridge, UK

How the company plans to use the capital

Microbiotica said proceeds will support the advancement of MB310 into Phase 2 clinical development in ulcerative colitis, following positive results from its Phase 1b COMPOSER-1 study. The company described the planned Phase 2 study as randomised, double-blind and placebo controlled.

Why this matters for GTM teams

All existing Series B investors participated in the financing, which was led by British Business Bank, according to Microbiotica.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Microbiotica Series C announcement.